Literature DB >> 7878565

Studies using radiolabelled aerosols in children.

M L Everard1.   

Abstract

Entities:  

Keywords:  Biomedical and Behavioral Research

Mesh:

Substances:

Year:  1994        PMID: 7878565      PMCID: PMC475337          DOI: 10.1136/thx.49.12.1259

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  59 in total

1.  How much nebulised budesonide reaches infants and toddlers?

Authors:  K C Lødrup Carlsen; K Nikander; K H Carlsen
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

2.  Drug delivery from jet nebulisers.

Authors:  M L Everard; A R Clark; A D Milner
Journal:  Arch Dis Child       Date:  1992-05       Impact factor: 3.791

3.  Variability in the measurement of nebulized aerosol deposition in man.

Authors:  S H Thomas; M J O'Doherty; C J Page; T O Nunan
Journal:  Clin Sci (Lond)       Date:  1991-12       Impact factor: 6.124

Review 4.  Nebulizer possibilities and limitations.

Authors:  H Matthys
Journal:  J Aerosol Med       Date:  1991

5.  Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler.

Authors:  S P Newman; F Morén; E Trofast; N Talaee; S W Clarke
Journal:  Eur Respir J       Date:  1989-03       Impact factor: 16.671

6.  Effect of nebulised aerosol size on lung deposition in patients with mild asthma.

Authors:  M M Clay; S W Clarke
Journal:  Thorax       Date:  1987-03       Impact factor: 9.139

7.  Experimental determination of the regional deposition of aerosol particles in the human respiratory tract.

Authors:  W Stahlhofen; J Gebhart; J Heyder
Journal:  Am Ind Hyg Assoc J       Date:  1980-06

8.  Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection.

Authors:  G C Smaldone; J Fuhrer; R T Steigbigel; M McPeck
Journal:  Am Rev Respir Dis       Date:  1991-04

9.  Therapeutic aerosols in children.

Authors:  S H Thomas; S Batchelor; M J O'Doherty
Journal:  BMJ       Date:  1993-07-24

10.  Does 99Tcm human serum albumin alter the characteristics of nebulized pentamidine isethionate?

Authors:  M J O'Doherty; S Thomas; C Page; A R Clark; D Mitchell; E Heduan; T O Nunan; N T Bateman
Journal:  Nucl Med Commun       Date:  1989-07       Impact factor: 1.690

View more
  8 in total

Review 1.  Management of acute pediatric asthma.

Authors:  John C Carl; Carolyn M Kercsmar
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

Review 2.  Ethical aspects of using radiolabelling in aerosol research.

Authors:  M L Everard
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

Review 3.  Treatment of childhood asthma. Options and rationale for inhaled therapy.

Authors:  C V Powell; M L Everard
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

Review 4.  Nebuliser therapy in childhood.

Authors:  P W Barry; C O'Callaghan
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

5.  Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.

Authors:  Susanne R Youngren-Ortiz; Nishant S Gandhi; Laura España-Serrano; Mahavir B Chougule
Journal:  Kona       Date:  2015-09-30       Impact factor: 2.897

6.  Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears!

Authors:  I Amirav; I Balanov; M Gorenberg; D Groshar; A S Luder
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

7.  Evaluating Drug Deposition Patterns from Turbuhaler® in Healthy and Diseased Lung Models of Preschool Children.

Authors:  Ravishekar Kannan; Ryan Arey; Andrzej Przekwas; Ariel Berlinski; Narender Singh
Journal:  J Pulm Med Respir Care       Date:  2022

8.  Controlled inhalation improves central and peripheral deposition in cystic fibrosis patients with moderate lung disease.

Authors:  Crystal Bourke; Sunalene Devadason; William Ditcham; Julie Depiazzi; Mark L Everard
Journal:  J Paediatr Child Health       Date:  2022-02-17       Impact factor: 1.929

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.